Voyager Therapeutics Announced That The Joint Steering Committee With Its Collaborator Neurocrine Biosciences Has Selected A Lead Development Candidate In Friedreich's Ataxia Program. The Companies Expect The Program To Advance Into Human Trials In 2025
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics and Neurocrine Biosciences have selected a lead development candidate for Friedreich's Ataxia, planning to advance into human trials in 2025. The candidate utilizes a frataxin gene replacement payload and a novel capsid from Voyager's TRACER platform.
February 26, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences, in collaboration with Voyager Therapeutics, is advancing a lead development candidate for Friedreich's Ataxia, aiming for human trials in 2025.
Neurocrine Biosciences' collaboration with Voyager Therapeutics on advancing a candidate for Friedreich's Ataxia into human trials by 2025 highlights the company's commitment to innovative treatments, potentially positively impacting its stock value.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Voyager Therapeutics has made significant progress in its collaboration with Neurocrine Biosciences, advancing a lead candidate for Friedreich's Ataxia into human trials by 2025.
The advancement of a lead development candidate into human trials represents a significant milestone for Voyager Therapeutics, potentially boosting investor confidence and stock value due to the progress in their collaboration with Neurocrine Biosciences.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90